What is Spravato?

Spravato® is a groundbreaking FDA-approved nasal spray treatment for adults struggling with treatment-resistant depression (TRD) or major depressive disorder (MDD) with suicidal thoughts. It offers a rapid-acting alternative for individuals who haven't found relief with traditional antidepressants. Spravato™ must be administered at a Spravato™ REMS certified health care center, such as Avana Wellness Center.

*As of January 2025, the FDA has approved Spravato for use without an oral antidepressant, making monotherapy an option for patients with (TRD)

Who is Eligible for Spravato?

  • Adults 18+
  • Have Treatment-Resistant Depression (TRD) (failed at least 2 different antidepressants)
  • Have Major Depressive Disorder (MDD) with suicidal ideation

Insurance & Financial Support

  • Spravato is covered by most major private insurers (Cigna, BCBS, UnitedHealthcare), Medicare, Medicaid plans, when criteria are met. This often includes cases of treatment-resistant depression where prior antidepressants have not been effective.
  • Spravato withMe saving program-Offered by Janssen (the manufacturer of Spravato) to help eligible patients lower their out-of-pocket costs for Spravato treatment.
  • Spravato WithMe Observation Rebate Program-is designed to help commercially insured patients cover the cost of the mandatory 2‑hour post‑treatment observation period.